James T Hagen Selected Research

Ovarian Neoplasms (Ovarian Cancer)

11/2022

Intrinsic adaptations in OXPHOS power output and reduced tumorigenicity characterize doxorubicin resistant ovarian cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James T Hagen Research Topics

Disease

5	Neoplasms (Cancer) 04/2024 - 01/2019
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2024 - 03/2023
2	Leukemia 03/2023 - 01/2022
1	Myocardial Infarction 01/2024
1	Ovarian Neoplasms (Ovarian Cancer) 11/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021

Drug/Important Bio-Agent (IBA)

3	Adenosine Triphosphate (ATP)IBA 04/2024 - 01/2021
2	Electron Transport Complex I (NADH-CoQ Reductase)IBA 11/2022 - 01/2022
1	EnzymesIBA 01/2024
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2024
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 10/2023
1	ProteomeIBA 10/2023
1	CeramidesIBA 03/2023
1	CaspasesIBA 03/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	SphingolipidsIBA 01/2022
1	P(1),P(5)- di(adenosine- 5'- )pentaphosphateIBA 01/2022
1	CalciumIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Adenylate KinaseIBA 01/2022
1	AcidsIBA 01/2019

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 04/2024 - 01/2022